Esomeprazole

What it is

Esomeprazole is a synthetic small molecule, a substituted benzimidazole, supplied as a magnesium salt in delayed-release (enteric-coated) capsules, tablets and granules, and as an injection. It is the single S-isomer of omeprazole, which is sold as a mixture of the S- and R- forms, and it was first approved in the United States in 2001. The molecule is unstable in acid, which is why oral forms are enteric coated so they survive the stomach and are absorbed in the small bowel. It is a prescription and, at the lower 20 mg strength, an over-the-counter medicine, not a nutrient and not present in food.

What the research says

The strongest evidence is for healing acid-damaged oesophagus: in randomised endoscopy-controlled trials about 93 out of 100 people with erosive oesophagitis have their erosions healed after 8 weeks on esomeprazole 40 mg daily. It also raises Helicobacter pylori cure rates when combined with two antibiotics, and lowers the rate of new stomach ulcers in people who must keep taking NSAIDs. It does not treat things acid suppression was hoped to fix: a 402-person placebo-controlled trial in poorly controlled asthma without reflux symptoms found no benefit at all. Long-term use carries documented costs: rebound acid symptoms on stopping, rare but serious low magnesium, vitamin B-12 malabsorption after years of use, and an association with fracture in observational data.

Evidence grade: Well established.

How it works

Drug class: Proton pump inhibitor (substituted benzimidazole); the S-enantiomer of omeprazole

Esomeprazole is taken up by the acid-producing (parietal) cells of the stomach lining, where the acid environment converts it into its active form. That active form binds to and blocks the H+/K+ ATPase - the 'proton pump' - which is the last step in pumping hydrogen ions into the stomach. Because it blocks the final common step, it reduces acid made in response to food, to gastrin and to any other stimulus. (Source 1)

What it is used for

• Endoscopy-verified healing is the best documented effect. In a 2025 randomised double-blind active-controlled phase 3 trial, 92.8% of the esomeprazole 40 mg group had healed erosions at 8 weeks, and the trial's own sample-size calculation was built on a prior literature figure of 93%. Evidence: established. (Source 2)
• Approved for 4 weeks of symptomatic GERD treatment and for maintenance of healed erosive oesophagitis, but the regulator's own label notes that controlled maintenance studies do not run beyond 6 months, so longer-term benefit has not been trialled. Evidence: established. (Source 3)
• In at-risk long-term NSAID users, esomeprazole kept most people ulcer-free: a 1-year Japanese study estimated a 95.9% ulcer-free rate, and the 6-month placebo-controlled VENUS and PLUTO studies gave esomeprazole ulcer-free rates of 94.7% and 94.8%. Evidence: established. (Source 4)
• Only as part of a three-drug regimen. Two randomised double-blind studies found eradication rates significantly higher with esomeprazole plus amoxicillin plus clarithromycin than with esomeprazole plus clarithromycin or esomeprazole alone (84% vs 55% per-protocol in study 191). Evidence: established. (Source 5)
• A 402-participant, 24-week, double-masked placebo-controlled trial of esomeprazole 40 mg twice daily found no benefit on the rate of episodes of poor asthma control (2.5 vs 2.3 events per person-year, P=0.66) or on any secondary outcome, and pH-probe-documented reflux did not identify a subgroup that benefited. Evidence: not-supported. (Source 6)
• Approved with an individualised regimen starting at 40 mg twice daily; the label records doses up to 240 mg/day having been given, and no outcome trial base comparable to the oesophagitis programme exists for this rare indication. Evidence: limited. (Source 3)

Interactions

• Clopidogrel (pharmacokinetic study): Esomeprazole blocks the liver enzyme CYP2C19 that turns clopidogrel into its active, platelet-blocking form, so measured platelet inhibition falls. The label says to avoid the combination and consider a different antiplatelet drug. Pooled randomised trial data, however, did not show a worse cardiovascular outcome, and showed fewer gastrointestinal bleeds on the PPI. (Source 7)
• Clopidogrel (randomised outcome evidence) (clinical trial): Pooled randomised trials in people on clopidogrel, nearly all of whom received omeprazole or esomeprazole, found no measurable loss of cardiovascular protection and a lower rate of overt gastrointestinal bleeding, at moderate GRADE certainty. (Source 8)
• St John's wort (Hypericum perforatum) (label): St John's wort switches on the liver enzymes CYP2C19 and CYP3A4 that clear esomeprazole, so blood levels of esomeprazole drop substantially and it may stop working. The label says to avoid taking the two together. (Source 9)
• Magnesium and calcium (as supplements and as blood levels) (case reports): Prolonged PPI use can drive blood magnesium down, sometimes to the point of tetany, arrhythmias or seizures, and low magnesium can in turn drag down calcium and potassium. The label suggests checking magnesium before starting and periodically in people on prolonged treatment or on digoxin or diuretics, and supplementing magnesium and/or calcium where needed. (Source 9)
• Vitamin B-12 (cyanocobalamin) (case reports): Because stomach acid is needed to free vitamin B-12 from food, several years of acid suppression can reduce B-12 absorption, and deficiency has been reported. (Source 9)
• Iron salts and other drugs whose absorption needs stomach acid (theoretical): Esomeprazole raises stomach pH, which changes how much of an acid-dependent substance is absorbed. The label groups iron salts with erlotinib, dasatinib, nilotinib, mycophenolate mofetil and ketoconazole/itraconazole as drugs dependent on gastric pH for absorption. The asthma trial excluded people on iron supplements on the grounds that they could interact with PPIs. (Source 9)

Stopping it

• Stopping is not neutral. In randomised, double-blind, placebo-controlled trials in people who had no acid symptoms to begin with, 44% developed heartburn, regurgitation or dyspepsia after the drug was withdrawn - significantly more than placebo. This is rebound acid hypersecretion: gastrin rises during treatment and acid output overshoots when the pump block is removed. (Source 10)
• Rebound symptoms typically start 5 to 14 days after stopping and last 4 to 5 days on average, but in one study 38% of affected people only developed symptoms at 3 to 4 weeks - which means short follow-up studies can miss it entirely. (Source 11)
• Duration of treatment appears to matter: acid-related symptoms were found after 4 and 8 weeks of PPI use in the two randomised volunteer trials, while treatment courses of about 2 weeks or less have not produced them, and after more than a year of treatment rebound hypersecretion lasted more than 8 weeks but less than 26 weeks. (Source 11)

What goes wrong

Withdrawing esomeprazole after 8 weeks caused new acid-related symptoms in 44% of previously symptom-free healthy volunteers, versus significantly fewer on placebo. (Source 10)

• Randomized trial, Moderate certainty.
• Size: 120 asymptomatic healthy volunteers (esomeprazole 40 mg/day trial); a parallel 48-volunteer pantoprazole trial gave the same 44%.
• Who: healthy volunteers with no baseline acid symptoms.
• How long: 56 days of PPI, 28 days of follow-up after stopping.
• Result: 44% developed acid-related symptoms after discontinuation, significantly higher than placebo; heartburn or regurgitation in 77% (20/26) of affected subjects and dyspepsia in 42% (11/26)
• Funding: not stated in the review.

the same proportion of subjects (44%) developed acid-related symptoms after the discontinuation of PPI therapy, which were significantly higher than those of the control group with placebo.

Long-term PPI use is associated with a modestly higher fracture risk in pooled observational data, with the association larger for longer use and heavily heterogeneous. (Source 12)

• Meta-analysis, Very low certainty.
• Size: 85 ratios from 2,714,502 individuals; 33 studies met the eligibility criteria.
• Who: adults using PPIs versus non-users in cohort and case-control studies.
• How long: mean follow-up 73.12 months (range 12-150 months)
• Result: Pooled effect size 1.28 (95% CI 1.22-1.35), I2=89.7%, P<0.00001; by site, hip 1.34 (1.24-1.46) and spine 1.18 (0.93-1.42); by duration, 1.29 (1.19-1.40) for short use rising to 1.62 (1.33-1.90) for long use. The same review found no difference in bone mineral density between PPI users and non-users. The included studies are observational, so this is an association and not a demonstrated cause, and heterogeneity was very high.
• Funding: not stated.

Limit of this finding: The paper's duration results are printed with mismatched brackets - for example 'pooled OR 1.29 (95% CI, 1.19-1.40); I2=69.1%; P=0.001)' closes a bracket that was never opened. The numbers themselves are intact; the stray bracket is a typesetting fault, not a missing figure. Note also that every study pooled here is observational, so the higher fracture rate in PPI users is an association. It is not evidence that the drug caused the fractures, and the same review found no difference in bone density.

pooling of the OR, HR, and RR revealed an effect size of 1.28 (95% CI, 1.22–1.35) (85 ratios from 2,714,502 individuals; I2=89.7%; P<0.00001; Supplementary Fig. 2).

Symptomatic and asymptomatic low blood magnesium has been reported with PPIs used three months or longer, most often after a year, and can be serious. (Source 9)

• Official position, Low certainty.
• Size: case reports and postmarketing reports summarised by the regulator.
• Who: patients on prolonged PPI therapy.
• How long: at least three months, in most cases after a year.
• Result: Serious events reported include tetany, arrhythmias and seizures; hypomagnesemia may cause hypocalcemia and/or hypokalemia; most cases needed magnesium replacement and PPI discontinuation.
• Funding: not applicable.

Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.

Daily acid suppression for longer than about three years may cause vitamin B-12 malabsorption. (Source 9)

• Official position, Low certainty.
• Size: rare reports in the literature summarised by the regulator.
• Who: long-term users of acid-suppressing medicines.
• How long: longer than 3 years.
• Result: Malabsorption of cyanocobalamin caused by hypo- or achlorhydria; rare reports of deficiency.
• Funding: not applicable.

Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B-12) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed.

What the evidence supports

In a randomised double-blind active-controlled phase 3 trial, esomeprazole 40 mg daily healed erosive oesophagitis in 92.8% of patients by 8 weeks. (Source 2)

• Randomized trial, Moderate certainty.
• Size: 261 randomised; 129 to esomeprazole 40 mg/day.
• Who: Chinese adults with endoscopically confirmed erosive oesophagitis (LA grade A-D)
• How long: 8 weeks.
• Result: Cumulative endoscopic healing at 8 weeks 92.8% esomeprazole vs 91.1% tegoprazan (difference -1.7%, 95% CI -8.5% to 5.0%); per-protocol 94.9% vs 92.3%. Adverse events were reported by 61.7% (79/128) of the esomeprazole group and 71.5% (93/130) of the tegoprazan group; 0 serious AEs in the esomeprazole arm.
• Funding: not stated in the extracted text; the trial was of a commercial comparator drug (tegoprazan) against esomeprazole.

The cumulative endoscopic healing rate at 8 weeks in the tegoprazan group was non-inferior to that of the esomeprazole group (91.1% vs . 92.8%, difference: −1.7%, 95% confidence interval [CI]: −8.5%, 5.0%, P = 0.008).

The 93% 8-week healing figure for esomeprazole 40 mg is the established prior estimate from earlier trials, not a single result. (Source 13)

• Randomized trial, Moderate certainty.
• Size: cited from four prior randomised trials.
• Who: adults with erosive oesophagitis.
• How long: 8 weeks.
• Result: Prior literature figure used for powering: 93% healed at week 8 on esomeprazole 40 mg.
• Funding: not stated.

Based on previous results of healed EE at week 8 of 93% for esomeprazole 40 mg, [ 22 , 23 , 24 , 25 ] the sample size in the present study was calculated as 103 subjects per treatment group.

In long-term NSAID users with a peptic ulcer history, esomeprazole kept most people ulcer-free, but the placebo-controlled trials that support this were only 6 months long. (Source 4)

• Randomized trial, Moderate certainty.
• Size: VENUS and PLUTO (placebo-controlled, 6 months); plus a 1-year single-arm Japanese study.
• Who: adults on long-term non-selective NSAIDs or COX-2 inhibitors at risk of ulcer.
• How long: 6 months (VENUS, PLUTO); 1 year (Japanese study)
• Result: Estimated ulcer-free rate after 1 year 95.9% (Japanese study, no placebo arm); esomeprazole ulcer-free rates 94.7% (VENUS) and 94.8% (PLUTO), life-table estimates.
• Funding: the Japanese study was conducted by AstraZeneca-affiliated investigators; industry involvement in VENUS/PLUTO.

esomeprazole proved efficacious in preventing the recurrence of peptic ulcers in this at-risk patient population, with an overall estimated ulcer-free rate after 1 year of 95.9%.

Esomeprazole triple therapy eradicated H. pylori significantly more often than esomeprazole plus clarithromycin or esomeprazole alone. (Source 5)

• Randomized trial, Moderate certainty.
• Size: two multicentre randomised double-blind studies (study 191 n=196 and n=187 per-protocol; study 193 n=67)
• Who: adults with documented H. pylori infection and duodenal ulcer or a history of one.
• How long: 10 days of treatment, eradication assessed 4 weeks later.
• Result: Study 191 per-protocol cure: 84% ⁷⁸,⁸⁹ with esomeprazole + amoxicillin + clarithromycin vs 55% ⁴⁸,⁶² with esomeprazole + clarithromycin; intent-to-treat 77% vs 52%.
• Funding: manufacturer-sponsored registration studies.

H. pylori eradication rates, defined as at least two negative tests and no positive tests from CLOtest ® , histology and/or culture, at 4 weeks post-therapy were significantly higher in the esomeprazole magnesium delayed-release capsules, amoxicillin and clarithromycin group than in the esomeprazole magnesium delayed-release capsules and clarithromycin group or the esomeprazole magnesium delayed-release capsules alone group.

What the evidence does not support

Esomeprazole 40 mg twice daily produced no improvement in asthma control in poorly controlled asthmatics without frequent reflux symptoms. (Source 6)

• Randomized trial, High certainty.
• Size: 412 randomised, 402 analysed.
• Who: adults with asthma inadequately controlled on inhaled corticosteroids, with absent or minimal reflux symptoms; 40% had reflux documented by pH probe.
• How long: 24 weeks.
• Result: Episodes of poor asthma control 2.5 events/person-year on esomeprazole vs 2.3 on placebo, P=0.66; no effect on lung function, airways reactivity, asthma control, symptom scores, nocturnal awakenings or quality of life; no benefit in the pH-probe-positive subgroup.
• Funding: NIH-NHLBI and the American Lung Association; esomeprazole and placebo supplied under a grant from AstraZeneca.

Limit of this finding: The trial is reported with two different participant totals. Its abstract says 402 people 'were randomly assigned', but the paper's own Results section says 412 patients were randomised and that data from 10 patients in New Orleans were left out of the analysis after Hurricane Katrina. So 412 were randomised and 402 analysed. Read the 402 as the number analysed, not the number enrolled; it does not change the result, which was no benefit on any asthma outcome.

Episodes of poor asthma control occurred with similar frequency in the placebo and esomeprazole treatment groups (2.3 vs 2.5 events/person-year, respectively, P=0.66). There was no treatment effect with respect to components of the EPACs, or secondary outcomes including pulmonary function, airways reactivity, asthma control, symptom scores, nocturnal awakenings, or quality of life. GER documented by pH probe studies in 40% of participants with absent or minimal symptoms did not identify a subgroup benefitting from PPI treatment.

The asthma trial investigators concluded there was no treatment benefit on any primary or secondary asthma outcome after six months. (Source 14)

• Randomized trial, High certainty.
• Size: 412 randomised, 402 analysed.
• Who: as above.
• How long: 6 months.
• Result: No demonstrable benefit on the primary outcome or on asthma symptoms, nocturnal awakenings, quality of life or lung function; no difference between those with and without documented reflux.
• Funding: NIH-NHLBI and American Lung Association; drug supplied by AstraZeneca.

Limit of this finding: The trial is reported with two different participant totals. Its abstract says 402 people 'were randomly assigned', but the paper's own Results section says 412 patients were randomised and that data from 10 patients in New Orleans were left out of the analysis after Hurricane Katrina. So 412 were randomised and 402 analysed. Read the 402 as the number analysed, not the number enrolled; it does not change the result, which was no benefit on any asthma outcome.

After six months of treatment in 402 patients, we were not able to demonstrate any treatment benefit with respect to the primary outcome, the rate of episodes of poor asthma control, or secondary outcomes measuring asthma symptoms, nocturnal awakenings, quality of life, or lung function. Moreover, there was no difference in asthma outcomes between patients with documented reflux compared to those without.

Where the evidence is mixed

In placebo-comparable trial data, esomeprazole's common side effects were mild and close to comparator rates, with headache the most frequent. (Source 15)

• Randomized trial, Moderate certainty.
• Size: over 15,000 patients in trials; 1,240 on 20 mg, 2,434 on 40 mg, 3,008 on omeprazole 20 mg in four healing trials.
• Who: adults aged 18 to 84 in worldwide trials.
• How long: up to 6 to 12 months in long-term studies (over 2,900 patients)
• Result: Headache 5.5% (20 mg), 5% (40 mg), 3.8% (omeprazole 20 mg); diarrhoea no difference; nausea, flatulence, abdominal pain, constipation and dry mouth at similar rates; incidence during 6-month maintenance was similar to placebo.
• Funding: manufacturer trial programme.

The most frequently occurring adverse reactions (at least 1%) in all three groups were headache (5.5%, 5%, and 3.8%, respectively) and diarrhea (no difference among the three groups). Nausea, flatulence, abdominal pain, constipation, and dry mouth occurred at similar rates among patients taking esomeprazole magnesium delayed-release capsules or omeprazole.

In the asthma trial, more people stopped esomeprazole than placebo for side effects, but serious adverse events were fewer on the drug. (Source 16)

• Randomized trial, Moderate certainty.
• Size: 402 participants.
• Who: adults with poorly controlled asthma.
• How long: 24 weeks.
• Result: Discontinuation for adverse effects 9 (esomeprazole) vs 3 (placebo); serious adverse events 11 vs 16, P=0.29; asthma hospitalisations 3 vs 4; one death on esomeprazole following surgery for a bronchial carcinoid found during the study.
• Funding: NIH-NHLBI and American Lung Association; drug supplied by AstraZeneca.

Limit of this finding: These adverse-event counts come from the authors' own manuscript held in PubMed Central, which is not word for word the version printed in the New England Journal of Medicine. The manuscript gives 11 serious adverse events on esomeprazole against 16 on placebo; the published journal abstract gives 11 against 17. Treat the direction as reliable - fewer serious events on the drug - and the exact placebo count as uncertain by one.

Esomeprazole was generally very well tolerated, but slightly more participants discontinued treatment in the esomeprazole group than the placebo group because of adverse effects, 9 vs 3, respectively. However, the esomeprazole group had fewer serious adverse events than the placebo group (11 vs 16, P = 0.29) including 3 asthma hospitalizations in the esomeprazole group and 4 in the placebo group.

Adding a PPI, in practice almost always omeprazole or esomeprazole, did not measurably worsen clopidogrel's cardiovascular protection in pooled randomised data and reduced gastrointestinal bleeding. (Source 17)

• Systematic review, Moderate certainty.
• Size: 14 RCTs met criteria; the main efficacy pool was 4 RCTs with 4,341 patients; the safety pool was 1 RCT with 3,761 patients.
• Who: patients taking clopidogrel, 96% also on aspirin; 98% of PPI-exposed received (es)omeprazole.
• How long: varies by trial.
• Result: Cardiovascular composite RR 1.08 (95% CI 0.78-1.50), absolute risk difference 0.2 percentage points (95% CI -0.9 to 1.2), moderate certainty. Overt GI bleeding RR 0.13 (95% CI 0.03-0.59), absolute risk difference -0.7 percentage points (95% CI -1.1 to -0.3), i.e. 2 versus 15 events in 3,761 patients, moderate certainty.
• Funding: not stated.

In conclusion, concurrent use of a PPI probably does not largely affect clopidogrel efficacy, but probably reduces the risk of overt gastrointestinal bleeding.

Where the research disagrees

Whether taking esomeprazole or omeprazole alongside clopidogrel actually harms patients

• US prescribing information for esomeprazole magnesium (2023), regulatory position resting on pharmacokinetic and platelet-function studies: Avoid concomitant use of esomeprazole magnesium delayed-release capsules with clopidogrel. Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. (Source 7)
• Axelsson and colleagues, systematic review and meta-analysis of randomised trials (2025), systematic review and meta-analysis of 14 RCTs with GRADE certainty ratings: concurrent use of a PPI probably does not largely affect clopidogrel efficacy, but probably reduces the risk of overt gastrointestinal bleeding. (Source 17)

Whether long-term PPI use damages bone

• Nassar and Richter, updated systematic review and meta-analysis (2018), meta-analysis of observational studies, I2=89.7%: pooling of the OR, HR, and RR revealed an effect size of 1.28 (95% CI, 1.22–1.35) (85 ratios from 2,714,502 individuals (Source 12)
• The same meta-analysis, on bone mineral density, meta-analysis of standardised mean differences in bone mineral density within the same review, covering 11 studies: With respect to the cross-sectional BMD values, there was no significant difference between the PPI users and their non-user counterparts (SMD, 0.00; 95% CI, −0.18 to 0.19; P=0.96; I2=72%; P=0.0002; Fig. 4A). (Source 18)

How much

• Reference intake: There is no reference intake for a drug. Dose is set by the prescriber for the specific condition. As a position, the 2023 US label sets adult dosing by indication: 20 mg or 40 mg once daily for 4 to 8 weeks to heal erosive oesophagitis, 20 mg once daily for maintenance and for symptomatic GERD, and 20 mg or 40 mg once daily for NSAID ulcer risk reduction. (Source 3)
• Upper limit: No upper limit in the nutrient sense. As a position, the 2023 US label's highest listed regimen is for pathological hypersecretory conditions including Zollinger-Ellison syndrome, starting at 40 mg twice daily and individualised, with doses up to 240 mg/day recorded as having been administered; a maximum of 20 mg once daily is set for severe liver impairment (Child-Pugh Class C). (Source 3)
• Studied: 40 mg once daily for 8 weeks in a 2025 randomised active-controlled erosive oesophagitis trial (129 patients). (Source 2)
• Studied: 40 mg twice daily for 24 weeks in the placebo-controlled asthma trial (412 randomised, 402 analysed). (Source 19)
• Studied: 40 mg once daily for 10 days with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily in the H. pylori eradication studies. (Source 3)
• Studied: 40 mg once daily for 56 days in the randomised healthy-volunteer withdrawal trial that produced rebound symptoms. (Source 10)
• Studied: 20 mg once daily for 1 year in Japanese long-term NSAID users with a peptic ulcer history. (Source 4)

A common belief, and what the research shows

The belief: A PPI is a harmless stomach soother you can stay on indefinitely and stop whenever you like.

What the research shows: Two randomised, double-blind, placebo-controlled trials in healthy volunteers with no baseline symptoms found that 44% developed acid-related symptoms after the drug was stopped, significantly more than placebo - so the act of stopping can itself create the symptoms that seem to prove the drug was needed. Symptoms typically begin 5 to 14 days after withdrawal, which is why a short follow-up can miss them.

Questions and answers

What is it?

Esomeprazole is a manufactured medicine, not a nutrient. Chemically it is a substituted benzimidazole, supplied as a magnesium salt in delayed-release capsules. It is the single S-mirror-image form of omeprazole, which is sold as a mixture of both forms, and it was first approved in the United States in 2001. (Source 20)

What does it do in the body?

It shuts down the stomach's acid pump. Absorbed from the small bowel, it concentrates in the acid-producing cells of the stomach lining and blocks the H+/K+ ATPase that pumps hydrogen ions into the stomach. Because that pump is the final step, acid production falls whatever is stimulating it - food, gastrin or anything else. (Source 1)

Is it good or bad for you?

It depends entirely on the setting and the length of use. For an acid-damaged oesophagus it is one of the better-evidenced drugs in medicine: about 93 in 100 people heal within 8 weeks. Used for something acid is not causing - asthma without reflux symptoms - a 402-person placebo-controlled trial found no benefit at all, so the drug is then all risk and no gain. Over years there are real costs: rebound symptoms on stopping, rare serious low magnesium, B-12 malabsorption and an observational association with fracture. (Source 14)

How do you get more of it?

Esomeprazole is a prescription and over-the-counter drug, so the only way anyone gets it is by being prescribed or buying it, at the dose and duration a prescriber sets. Reported adult regimens in the 2023 label range from 20 mg once daily for symptomatic reflux to 40 mg twice daily as a starting point in Zollinger-Ellison syndrome. There are no foods or behaviours that raise esomeprazole levels; this section records what trials gave people and is not advice. (Source 3)

If it is harmful, what reduces it?

Where esomeprazole is doing harm, the literature's answer is to stop it - but stopping needs planning, because rebound acid hypersecretion produces new symptoms in about 44% of people who had none before. Symptoms typically begin 5 to 14 days after stopping and last about 4 to 5 days, though in one study 38% of affected people only got them at 3 to 4 weeks. In the reported cases of PPI-related low magnesium, treatment required magnesium replacement together with stopping the drug. (Source 9)

Why might someone be low in it or missing it?

Being 'low' in esomeprazole is not a deficiency state - nobody needs it. Blood levels can fall, though: St John's wort and rifampin switch on the CYP2C19 and CYP3A4 enzymes that clear it, and the label says levels can be substantially decreased and that these should not be taken together. Severe liver impairment goes the other way, and the label caps the dose at 20 mg once daily in Child-Pugh Class C. (Source 9)

Which whole foods contain it or feed it?

None. Esomeprazole is a synthetic small molecule made as a magnesium salt for delayed-release capsules; it does not occur in food and no whole food contains it or feeds it. What food does affect is the nutrients esomeprazole interferes with: because stomach acid is needed to release vitamin B-12 from food, several years of acid suppression can reduce B-12 absorption. (Source 20)

What happens if you do not have it?

Nothing happens from not taking it - it treats a condition, it does not supply anything the body needs. What the trials show is what happens to an untreated acid problem rather than to a person without the drug: in NSAID users with a previous ulcer, staying on esomeprazole gave an estimated 95.9% ulcer-free rate at one year, and the placebo arms of the 6-month VENUS and PLUTO studies are where the untreated comparison sits. (Source 4)

How can you test for it?

You do not test for the drug itself in ordinary care. What gets tested is the condition and the drug's known knock-on effects. Healing of erosive oesophagitis was measured by upper gastrointestinal endoscopy in the trials, read by two trained endoscopists; reflux itself was measured with ambulatory pH probe monitoring in the asthma trial. For the harms, the label suggests considering magnesium level monitoring before starting and periodically during prolonged treatment, and considering B-12 deficiency if symptoms consistent with it appear after long use. (Source 9)

References

1. DailyMed (US National Library of Medicine), labeller Mylan Pharmaceuticals Inc.. ESOMEPRAZOLE MAGNESIUM capsule, delayed release - Prescribing Information, 12.1 Mechanism of Action. 2023. Read the source
2. Chinese Medical Journal. Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase III trial. 2025. PMID 39474720, DOI 10.1097/CM9.0000000000003276. Read the source
3. DailyMed (US National Library of Medicine), labeller Mylan Pharmaceuticals Inc.. ESOMEPRAZOLE MAGNESIUM capsule, delayed release - Prescribing Information, Table 1 Recommended Dosage in Adults by Indication. 2023. Read the source
4. BMC Gastroenterology. Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. 2013. PMID 23530709, DOI 10.1186/1471-230X-13-54. Read the source
5. DailyMed (US National Library of Medicine), labeller Mylan Pharmaceuticals Inc.. ESOMEPRAZOLE MAGNESIUM capsule, delayed release - Prescribing Information, 14.5 H. pylori Eradication. 2023. Read the source
6. New England Journal of Medicine (author manuscript, PMC). Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma. 2009. PMID 19357404, DOI 10.1056/NEJMoa0806290. Read the source
7. DailyMed (US National Library of Medicine), labeller Mylan Pharmaceuticals Inc.. ESOMEPRAZOLE MAGNESIUM capsule, delayed release - Prescribing Information, 5.7 Interaction with Clopidogrel. 2023. Read the source
8. Basic & Clinical Pharmacology & Toxicology. Efficacy and Safety of Clopidogrel With and Without a Proton Pump Inhibitor: A Systematic Review and Meta-Analysis. 2025. PMID 40685887, DOI 10.1111/bcpt.70087. Read the source
9. DailyMed (US National Library of Medicine), labeller Mylan Pharmaceuticals Inc.. ESOMEPRAZOLE MAGNESIUM capsule, delayed release - Prescribing Information, 5.8-5.10 (B-12, hypomagnesemia, St. John's Wort). 2023. Read the source
10. International Journal of Molecular Sciences. Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive?. 2024. PMID 38791497, DOI 10.3390/ijms25105459. Read the source
11. International Journal of Molecular Sciences. Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive?. 2024. PMID 38791497, DOI 10.3390/ijms25105459. Read the source
12. Journal of Bone Metabolism. Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis. 2018. PMID 30237993, DOI 10.11005/jbm.2018.25.3.141. Read the source
13. Chinese Medical Journal. Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase III trial. 2025. PMID 39474720, DOI 10.1097/CM9.0000000000003276. Read the source
14. New England Journal of Medicine (author manuscript, PMC). Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma. 2009. PMID 19357404, DOI 10.1056/NEJMoa0806290. Read the source
15. DailyMed (US National Library of Medicine), labeller Mylan Pharmaceuticals Inc.. ESOMEPRAZOLE MAGNESIUM capsule, delayed release - Prescribing Information, 6.1 Clinical Trials Experience. 2023. Read the source
16. New England Journal of Medicine (author manuscript, PMC). Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma. 2009. PMID 19357404, DOI 10.1056/NEJMoa0806290. Read the source
17. Basic & Clinical Pharmacology & Toxicology. Efficacy and Safety of Clopidogrel With and Without a Proton Pump Inhibitor: A Systematic Review and Meta-Analysis. 2025. PMID 40685887, DOI 10.1111/bcpt.70087. Read the source
18. Journal of Bone Metabolism. Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis. 2018. PMID 30237993, DOI 10.11005/jbm.2018.25.3.141. Read the source
19. New England Journal of Medicine (author manuscript, PMC). Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma (abstract Methods). 2009. PMID 19357404, DOI 10.1056/NEJMoa0806290. Read the source
20. DailyMed (US National Library of Medicine), labeller Mylan Pharmaceuticals Inc.. ESOMEPRAZOLE MAGNESIUM capsule, delayed release - Prescribing Information, 11 DESCRIPTION. 2023. Read the source